Vivek Subbiah

Research interests

Publications

• The next generation of evidence-based medicine

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-022-02160-z

• Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-022-02103-8

• Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-023-02321-8

• Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.12.007

• Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.08.002

• Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

  Nature Medicine · 2022 · https://doi.org/10.1038/s41591-022-01931-y

• Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2021.12.014

• Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

  Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.22.00393

• Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

  The Lancet Oncology · 2022 · 10.1016/s1470-2045(22)00541-1

• Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

  The Lancet Diabetes & Endocrinology · 2021 · https://doi.org/10.1016/s2213-8587(21)00120-0

• Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00247-3

• Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

  ESMO Open · 2021 · 10.1016/j.esmoop.2021.100336

• Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30068-1

• Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30321-1

• Efficacy of Selpercatinib in RET -Altered Thyroid Cancers

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2005651

• Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?

  Trends in cancer · 2020 · https://doi.org/10.1016/j.trecan.2020.01.005

• RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

  Journal of Thoracic Oncology · 2020 · https://doi.org/10.1016/j.jtho.2020.01.006

• Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2005653

• The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

  Annals of Oncology · 2020 · 10.1016/j.annonc.2020.07.002

• Clinical Development of BRAF plus MEK Inhibitor Combinations

  Trends in cancer · 2020 · 10.1016/j.trecan.2020.05.009

• State-of-the-Art Strategies for Targeting RET -Dependent Cancers

  Journal of Clinical Oncology · 2020 · 10.1200/jco.19.02551

• Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

  Annals of Oncology · 2020 · 10.1016/j.annonc.2020.10.599

• Precision Targeted Therapy with BLU-667 for RET-Driven Cancers

  Cancer Discovery · 2018 · https://doi.org/10.1158/2159-8290.cd-18-0338

• BRAF Inhibition in BRAF V600 -Mutant Gliomas: Results From the VE-BASKET Study

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.78.9990

• Selective RET kinase inhibition for patients with RET-altered cancers

  Annals of Oncology · 2018 · 10.1093/annonc/mdy137

• Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.73.6785

• Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

  JAMA Oncology · 2017 · 10.1001/jamaoncol.2017.5029

• Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience

  Investigational New Drugs · 2017 · https://doi.org/10.1007/s10637-017-0534-0

• Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

  Clinical Cancer Research · 2016 · 10.1158/1078-0432.ccr-16-1432

• RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients

  Clinical Cancer Research · 2016 · 10.1158/1078-0432.ccr-16-1679

• Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1502309

Current projects

No projects listed.